Key Highlights

● Biofrontera Inc., the US commercial dermatology company behind the Ameluz photodynamic therapy system, reported first-quarter 2026 revenue growth of 17% and gross margin near 80%, while awaiting an FDA decision on a new skin-cancer indication.

● For full-year 2025, Biofrontera reported revenue of $41.7 million, up about 12% from $37.3 million in 2024, with gross margin of 73.7%, up from 50.1%.

● Bears note the company remains unprofitable on a full-year basis, with a $10.5 million net loss in 2025 and a widened first-quarter 2026 net loss.

● Investors should watch for the FDA's decision on the new skin-cancer indication for Ameluz.

Biofrontera Inc. (Nasdaq: BFRI), the Woburn, Massachusetts-based dermatology company that markets the Ameluz photodynamic therapy (PDT) system for actinic keratosis, told investors on May 14, 2026, that first-quarter revenue rose approximately 17% year-over-year to $10.1 million, while gross margin expanded to roughly 80%. The results followed a 2025 restructuring in which Biofrontera Inc. bought out the US rights to Ameluz and RhodoLED from its German affiliate, Biofrontera AG, a transaction management credits with much of the margin gain. The company also has an FDA decision pending later this year on expanding Ameluz's use to a form of skin cancer, a potential catalyst for a stock with a sub-$15 million market capitalization trading around $1.17.

What happened

In its May 14, 2026 release, Biofrontera reported first-quarter revenue of $10.1 million, up from $8.6 million a year earlier, attributed to roughly a 16% rise in Ameluz units sold plus a fourth-quarter 2025 price increase. Gross margin reached approximately 80%, up sharply from about 62% a year earlier. Net loss widened slightly to $4.8 million ($0.41 per share) from $4.2 million ($0.47 per share), while operating loss narrowed to $4.3 million from $4.5 million. Total operating expenses rose to $14.4 million from $13.1 million, driven by higher SG&A ($11.0 million versus $8.7 million) tied to selling, marketing and legal costs. Cash and equivalents stood at $6.3 million at quarter-end, down only modestly from $6.4 million at December 31, 2025, and operating cash used was just $70,000, versus $4.1 million burned a year earlier. CEO Hermann Luebbert said the company's cash consumption was "near zero" in the quarter.

Why the development matters

The combination of accelerating revenue and expanding gross margin is notable for a company that has posted consecutive annual net losses since 2023. The near-elimination of quarterly cash burn is significant given Biofrontera's thin cash cushion, suggesting the 2025 restructuring with Biofrontera AG has begun translating into improved unit economics rather than one-time accounting benefits. The pending FDA decision on superficial basal cell carcinoma (sBCC) represents a potential second indication for Ameluz beyond actinic keratosis, which could expand its addressable market if approved, though approval, timing and uptake are not guaranteed.

Company and product background

Biofrontera Inc. was incorporated in the United States in 2015 and listed on Nasdaq in October 2021. It commercializes Ameluz (aminolevulinic acid hydrochloride) topical gel combined with the RhodoLED lamp series, a photodynamic therapy approved in the US for actinic keratosis, a common precancerous skin condition. It previously operated under a licensing and transfer-pricing arrangement with its German affiliate, Biofrontera AG, which developed the underlying technology. In 2025, Biofrontera Inc. closed a transaction to acquire the US intellectual property, regulatory approvals and manufacturing rights for Ameluz and RhodoLED outright, reducing earnout payments owed on US net sales from a 25%-35% range to 12%-15%. It also divested its Xepi topical product for $3 million at closing plus contingent payments, and funded part of the transition through a Series C preferred stock issuance generating $10.85 million in net proceeds; shares outstanding rose from 8.87 million at the end of 2024 to about 12.8 million by mid-2026. In February 2026 the FDA accepted Biofrontera's supplemental New Drug Application for Ameluz-PDT in superficial basal cell carcinoma, with a target decision (PDUFA) date of September 28, 2026, based on a Phase 3 trial in which 65.5% of 187 patients achieved complete clearance versus 4.8% on placebo. Separately, the company reported positive Phase 3 data supporting expanded AK treatment on extremities, neck and trunk, and positive Phase 2b results for an acne indication (a 58% reduction in inflammatory lesions versus 37% for vehicle control), both earlier-stage than the sBCC filing.

Financial position

For full-year 2025, Biofrontera reported revenue of $41.7 million, up about 12% from $37.3 million in 2024, with gross margin of 73.7%, up from 50.1%. The fourth quarter alone delivered record revenue of $17.1 million, up 36% year-over-year, with gross margin of 82.4% and net income of $5.6 million, versus a $1.4 million net loss a year earlier. Full-year 2025 net loss was $10.5 million, narrower than the $17.7 million loss in 2024. Cash and equivalents were $6.4 million at December 31, 2025, and $6.3 million at March 31, 2026. Given the sharp reduction in first-quarter cash burn, near-term runway pressure appears eased, though the cash balance remains modest for a commercial-stage company, and continued margin improvement, rather than existing cash alone, appears central to management's stated goal of 2026 cash-flow breakeven. Investors should treat forward runway as management-dependent, given the company's history of financing rounds and share issuances.

Bull case

Bulls point to 17% revenue growth alongside gross margin near 80%, reflecting both organic Ameluz demand and the lower cost base following the Biofrontera AG asset buyout. Near-zero first-quarter cash burn, if sustained, would materially reduce financing risk. A favorable FDA decision on the sBCC indication by September 28, 2026, would add a second approved use for Ameluz in a disease affecting an estimated 3.6 million Americans annually with basal cell carcinoma, potentially broadening the prescriber base beyond actinic keratosis.

Risk case

Bears note the company remains unprofitable on a full-year basis, with a $10.5 million net loss in 2025 and a widened first-quarter 2026 net loss, and cash reserves of roughly $6 million leave limited margin for setbacks. The FDA could reject, delay, or restrict the sBCC label expansion. Patent litigation with Sun Pharmaceutical Industries, begun in mid-2024 in federal court and before the International Trade Commission, continues despite a February 2026 Patent Trial and Appeal Board ruling invalidating challenged claims of one Sun Pharma patent, since Sun Pharma can appeal and other claims remain contested. Share count has grown meaningfully since 2024, and the stock, at a market capitalization under $15 million with a 52-week low near $0.56, exhibits high volatility typical of small-cap biopharmaceutical names.

What investors should watch next

1. FDA action on the sBCC supplemental application by the September 28, 2026 PDUFA date.

Conclusion

Biofrontera's first-quarter 2026 results show a company whose restructured economics with its former German affiliate are showing up in better margins and cash discipline, even as it remains unprofitable overall. The pending FDA decision on a new skin-cancer indication adds a defined near-term catalyst. Whether the improved trajectory continues, and whether regulatory and litigation outcomes turn favorable, will determine whether recent gains mark a durable inflection or a temporary improvement for a still-small, cash-constrained company.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.